Europe is set to establish its first commercial orbital laboratory dedicated to cancer research, aiming to explore how tumors behave in microgravity. SPARK Microgravity GmbH announced its plans during a public session at Frontiers Science House in Davos, where it detailed the potential of this facility to uncover new drug targets that Earth’s gravity obscures.
The proposed lab will operate in low Earth orbit, allowing researchers to conduct experiments that are impossible in traditional, gravity-bound laboratories. According to SPARK Microgravity, this new environment could significantly reduce the timeline from discovery to therapy by providing unique biological insights.
Exploring Cancer in Microgravity
The discussion at the Davos session, titled “Curing cancer in space,” highlighted how microgravity might transform disease research. Allison Bajet, CEO and co-founder of SPARK Microgravity, explained the challenges of conducting experiments on Earth. She likened the difficulty of studying biology under gravity’s influence to listening to a symphony amid construction noise. “Going to space to experience real microgravity is like stepping into a soundproof room,” she stated, emphasizing the clarity this environment provides researchers.
In microgravity, gravity’s effects on cell growth, settlement, and interaction are eliminated, allowing scientists to observe cancer cells in a more natural state. The orbital lab will facilitate three-dimensional tumor growth experiments that more accurately reflect cancer behavior in the human body. Additionally, researchers will be able to investigate cell signaling without the distortions typically caused by gravity.
Collaborations and Future Missions
SPARK Microgravity is collaborating with several organizations to make this vision a reality. Partnerships with Axiom Space and Voyager Technologies will provide the necessary infrastructure for research operations. Furthermore, ATMOS Space Cargo will support future return missions to transport biological samples back to Earth for further analysis. The company stresses that reliable return capability is crucial for translating research findings into clinical applications.
An early flight demonstration is scheduled for May 2024, with support from the Swedish Space Corporation. This mission will test the systems designed for the upcoming cancer experiments. Additionally, SPARK Microgravity plans to collaborate with HyPrSpace to launch cancer research using the Baguette-One rocket, which is poised to be the first vehicle launched from France.
The announcement made at Davos aims to bring attention to the intersection of scientific research and global policymaking. Organizers believe that such platforms can accelerate the development of science-driven solutions. SPARK Microgravity envisions the orbital lab as a pivotal step toward normalizing space-based research, thereby integrating microgravity studies into standard drug development practices.
As the project progresses, it could not only advance the understanding of cancer but also redefine how medical research is conducted beyond the confines of Earth.
